Abstract The performance of the Xpert MRSA polymerase chain reaction (PCR) assay on pooled nose, groin, and throat swabs (three nylon flocked eSwabs into one tube) was compared to culture by analyzing 5,546 samples. The sensitivity [0.78, 95 % confidence interval (CI) 0.73-0.82] and specificity (0.99, 95 % CI 0.98-0.99) were similar to the results from published studies on separated nose or other specimens. Thus, the performance of the Xpert MRSA assay was not affected by pooling the three specimens into one assay, allowing a higher detection rate without increasing laboratory costs, as compared to nose samples alone.
Introduction
The rapid and accurate detection of methicillin-resistant Staphylococcus aureus (MRSA) carriers helps to reduce the risk of transmission to other patients. Rapid polymerase chain reaction (PCR)-based methods enable to confirm or refute MRSA carriage in patients within 2 h. Most of them were evaluated with nose specimens, whereas studies showed that multiple site sampling increases the sensitivity of MRSA detection [1] [2] [3] [4] [5] [6] .
The high price of commercially available rapid PCR tests for MRSA screening leads some laboratories to pool specimens of the same patient into one single assay [7] , whereas others consider that these tests are not cost-effective [8] .
Some studies addressed the effect of pooling nose and groin samples on tests' performances [9, 10] . As both throat and groin are additional important sites for MRSA detection [1, 5, 6] , validation of the Xpert MRSA assay (Cepheid, Sunnyvale, CA, USA) carried out on these three swabs was required. Most of these studies were done using the Cepheid collection device (Venturi Transystem; Copan, Brescia, Italy). The new eSwab device (Copan) is increasingly used because it is suitable for the automated inoculation of agar plates, and is more sensitive to recovering bacteria by culture, including MRSA screening [11] [12] [13] . Therefore, we aimed to assess the performance [sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPP)] of the Xpert MRSA assay on pooled nose, throat, and groin specimens using eSwabs and culture as the gold standard.
Materials and methods
Screening samples (nose, groin, and throat) were performed using the eSwab MRSA system (Copan). This collecting device is composed of a screw-cap tube filled with 1 ml of Amies liquid and three swabs with flocked nylon fiber tips. Xpert MRSA tests were performed according to the manufacturer's instructions, except that 100 μL of the Amies liquid were used to perform the analysis. For culture, about 250 μl of the Amies liquid were inoculated into mStaphylococcus broth (Difco, Basel, Switzerland) and incubated overnight at 35°C. The broth was then inoculated onto chromogenic MRSA-Select agar (Bio-Rad, Marnes-laCoquette, France) and incubated overnight at 35°C [14] . The DNase and agglutination (Slidex Staph Plus; bioMérieux, Marcy-l'Etoile, France) tests were performed to confirm the identification of S. aureus. Susceptibility to oxacillin was determined by the cefoxitin disk diffusion method according to the Clinical and Laboratory Standards Institute (CLSI) recommendations [15] . The sensitivity, specificity, PPV, and NPV of the Xpert MRSA assay, and their 95 % confidence intervals (CIs), were calculated using the online calculator at http://faculty.vassar.edu/lowry/ clin1.html.
Results
To assess the effect of pooling samples on rapid MRSA detection, we performed a preliminary investigation. Nose, groin, and throat sites of 50 known MRSA carriers were first swabbed with separate eSwab devices (three swabs in three separated tubes) and then with the eSwab MRSA system (three swabs in one tube). Each specimen (tube) was analyzed by the Xpert MRSA assay and culture. In addition, 150 μl of nose, groin, and throat separate samples were pooled at the laboratory before analysis. With the Xpert MRSA test, separate analyses of the nose, throat, and groin yielded a total of 38 (76 %) positive patients (Table 1) , whereas when specimens were pooled, either by the nurses or at the laboratory, 34 (68 %) and 35 (70 %) patients were positive, respectively. Similar results were obtained with culture (Table 1) . Thus, a loss in sensitivity of only 6 % could be attributed to pooling. This reduction is largely compensated by the benefit of adding throat and groin samples, which, overall, increases the detection from 52 % and 54 % to 76 % and 78 % for the Xpert MRSA test and culture, respectively (Table 1) . These results are similar to the data reported in a larger study [1] . The sensitivities of the Xpert MRSA assay compared to culture as the gold standard were not significantly different regarding the site of sampling or the pooling protocol (harvested in one tube by nurses or pooled at the laboratory) ( Table 1) and were similar to the 86 % sensitivity (95 % CI 0.81-0.91) reported by the manufacturer. Thus, we chose the eSwab MRSA system (three swabs in one tube) for a larger evaluation.
From July 2011 to May 2012, 5,555 pooled samples (nose, groin, and throat) from 3,774 patients were analyzed by both the Xpert MRSA assay and culture. Only nine samples (0.16 %) showed invalid results after being tested twice by the Xpert MRSA assay, and were excluded from the analysis. These results are similar to previously reported studies on the Xpert MRSA assay [7, 10, [16] [17] [18] [19] [20] [21] .
Discussion
Whether the Xpert MRSA test is adequate for detecting MRSA carriers is an important question. Among the 335 new MRSA carriers identified during this period, 37 (11 %) would have been missed if culture would not have been performed, a ratio similar to a previous report [22] . There are several reasons for that. Some studies report the failure of the Xpert MRSA assay to detect strains harboring SCCmec variants [20, 23] or the newly described mecC [24] . In our study, among the 65 false-negative results, 45 isolates were tested by the Xpert MRSA/SA nasal test (PCRs for mecA and SCCmec-chromosome junction) and were positive (data not shown). Moreover, at least 50 (77 %) were due to MRSA strains belonging to four predominant clones in our area (data not shown), which are usually correctly identified by the Xpert MRSA assay (ST45-IV, ST5-II, ST228-I, and ST8-VI; [25] ). This indicates that the majority of false-negative results were not due to SCCmec variants. Another explanation could be the lower performance of the Xpert MRSA assay compared to culture. This hypothesis is supported by a study reporting a If one or more sites were positive, the pooled result was considered to be positive. It was considered to be negative only when the three sites were all negative that the limit of detection of enrichment culture was about 15 times lower (40 CFU/ml) than the Xpert MRSA PCR (610 CFU/ml) [18] . In this work, we also observed 68 false-positive results. Among these, 33 (49 %) were due to the presence of methicillin-sensitive S. aureus strains that did not possess the mecA gene, but still possessed part of the SCCmec gene and the chromosome targeted by the Xpert MRSA test (detected according to a previously described protocol [22] ). False-positive results could also be due to the presence of dead MRSA cells in former carriers.
In conclusion, the high NPV (99 %) of the Xpert MRSA assay that we observed when pooling nose, throat, and groin samples supports the use of this procedure to detect MRSA and to rapidly stop or avoid unnecessary preemptive isolation measures. By pooling these samples, we increased the efficiency of MRSA screening without increasing the laboratory costs. Moreover, by using the eSwab system, automated inoculation is possible.
